Drugs / antigen-specific CTLs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04276896 | Jun 2026 → Dec 2029 expected | COVID-19 | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | antigen-specific CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04276896 ↗ |
| Modality | Cell therapy | “antigen-specific cytotoxic T cell vaccines” NCT04276896 ↗ |
| Route | Intravenous | “5x10\^6 cells of LV-DC vaccine and 1x10\^8 antigen-specific CTLs via sub-cutaneous injection and IV infusion, respectively.” NCT04276896 ↗ |